Korea Bio-Gen Co.Ltd (318000) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Korea Bio-Gen Co.Ltd (318000) has a cash flow conversion efficiency ratio of 0.040x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩1.85 Billion ≈ $1.25 Million USD) by net assets (₩46.23 Billion ≈ $31.33 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Korea Bio-Gen Co.Ltd - Cash Flow Conversion Efficiency Trend (2017–2024)
This chart illustrates how Korea Bio-Gen Co.Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read 318000 current and long-term liabilities for a breakdown of total debt and financial obligations.
Korea Bio-Gen Co.Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Korea Bio-Gen Co.Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Gurktaler AG ST
VI:GAGS
|
-0.006x |
|
ABVC Biopharma Inc
NASDAQ:ABVC
|
-0.044x |
|
Minerva Neurosciences Inc
NASDAQ:NERV
|
0.084x |
|
Vibhor Steel Tubes Limited
NSE:VSTL
|
N/A |
|
India Globalization Capital Inc
NYSE MKT:IGC
|
-0.258x |
|
FN REPUBLIC Co. Ltd
KQ:064090
|
0.025x |
|
Hanwha Investment&Securities Co Ltd Pref
KO:003535
|
-0.112x |
|
Advancecon Holdings Bhd
KLSE:5281
|
0.102x |
Annual Cash Flow Conversion Efficiency for Korea Bio-Gen Co.Ltd (2017–2024)
The table below shows the annual cash flow conversion efficiency of Korea Bio-Gen Co.Ltd from 2017 to 2024. For the full company profile with market capitalisation and key ratios, see market cap of Korea Bio-Gen Co.Ltd.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ₩44.91 Billion ≈ $30.44 Million |
₩4.29 Billion ≈ $2.91 Million |
0.096x | -57.57% |
| 2023-12-31 | ₩42.05 Billion ≈ $28.50 Million |
₩9.47 Billion ≈ $6.42 Million |
0.225x | +371.25% |
| 2022-12-31 | ₩34.95 Billion ≈ $23.68 Million |
₩1.67 Billion ≈ $1.13 Million |
0.048x | -51.19% |
| 2021-12-31 | ₩31.61 Billion ≈ $21.42 Million |
₩3.09 Billion ≈ $2.10 Million |
0.098x | +6.83% |
| 2020-12-31 | ₩28.16 Billion ≈ $19.09 Million |
₩2.58 Billion ≈ $1.75 Million |
0.092x | -22.91% |
| 2019-12-31 | ₩25.69 Billion ≈ $17.41 Million |
₩3.05 Billion ≈ $2.07 Million |
0.119x | -34.28% |
| 2018-12-31 | ₩10.97 Billion ≈ $7.44 Million |
₩1.98 Billion ≈ $1.34 Million |
0.181x | +16.60% |
| 2017-12-31 | ₩8.93 Billion ≈ $6.05 Million |
₩1.38 Billion ≈ $938.31K |
0.155x | -- |
About Korea Bio-Gen Co.Ltd
KBG Corp. produces and supplies a range of fine chemicals in South Korea and internationally. The company offers silicone chemicals, such as functional organosilanes, functional silicone polymers, silicone resins and intermediates, silicone pressure sensitive adhesives, and silicone materials for electronics; specialty chemicals, including polymerization inhibitors; and food additives, as well as… Read more